Indinavir impairs endothelial function in healthy HIV-negative men -: art. no. 933.e2

被引:68
作者
Shankar, SS
Dubé, MP
Gorski, JC
Klaunig, JE
Steinberg, HO
机构
[1] Indiana Univ, Sch Med, Dept Med, Div Infect Dis, Indianapolis, IN 46202 USA
[2] Indiana Univ, Sch Med, Dept Med, Div Endocrinol, Indianapolis, IN 46202 USA
[3] Indiana Univ, Sch Med, Dept Med, Div Clin Pharmacol, Indianapolis, IN 46202 USA
[4] Indiana Univ, Sch Med, Dept Med, Div Pharmacol & Toxicol, Indianapolis, IN 46202 USA
关键词
D O I
10.1016/j.ahj.2005.06.005
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Potent antiretroviral treatment has drastically reduced mortality in HIV-infected patients but may accelerate atherosclerotic disease, which could be partially mediated via endothelial dysfunction. Methods In 8 HIV-negative healthy males, leg blood flow responses to intraartery infusions of methacholine chloride (Mch), sodium nitroprusside, and N-G-mono-methyl-L-arginine (L-NMMA) were measured before and after 4 weeks of daily oral indinavir. In the same subjects, we also assessed the effect of indinavir on lipids, insulin sensitivity, markers of inflammation, as well as oxidative stress. Results After 4 weeks of indinavir, the endothelium-dependent response to methacholine chloride was impaired (195% +/- 38% vs 83% +/- 13%, P < .05), the response to N-G-mono-methyl-L-arginine (nitric oxide-dependent tone) was nearly abrogated (-30% +/- 4% vs -1% +/- 11%, P < .05), whereas the endothelium-independent response to sodium nitroprusside remained unchanged. Fasting insulin levels increased from 5.8 +/- 1.2 to 7.0 +/- 1.4 mu U/mL (P < .05), and HOMA-IR scores increased from 1.3 +/- 0.3 to 1.6 +/- 0.3 U (P < .05). There were no changes in blood pressure, lipids, markers of inflammation, or oxidative stress. Conclusions Four weeks of the HIV-1 protease inhibitor indinavir, in the absence of HIV-1 infection, causes vascular dysfunction most likely at the level of endothelial nitric oxide production. The vascular dysfunction may be mediated partially by the concomitant induction of insulin resistance but other mechanisms cannot be ruled out.
引用
收藏
页码:933.e1 / 933.e7
页数:7
相关论文
共 39 条
[1]   Long-term follow-up of patients with mild coronary artery disease and endothelial dysfunction [J].
Al Suwaidi, J ;
Hamasaki, S ;
Higano, ST ;
Nishimura, RA ;
Holmes, DR ;
Lerman, A .
CIRCULATION, 2000, 101 (09) :948-954
[2]  
[Anonymous], 1997, ARCH INTERN MED, V157, P2413, DOI [10.1001/archinte.1997.00440420033005, DOI 10.1001/ARCHINTE.1997.00440420033005]
[3]   EFFECTS OF CARBON-TETRACHLORIDE, MENADIONE, AND PARAQUAT ON THE URINARY-EXCRETION OF MALONDIALDEHYDE, FORMALDEHYDE, ACETALDEHYDE, AND ACETONE IN RATS [J].
BAGCHI, D ;
BAGCHI, M ;
HASSOUN, E ;
MOSER, J ;
STOHS, SJ .
JOURNAL OF BIOCHEMICAL TOXICOLOGY, 1993, 8 (02) :101-106
[4]   RATES AND TISSUE SITES OF NON-INSULIN-MEDIATED AND INSULIN-MEDIATED GLUCOSE-UPTAKE IN HUMANS [J].
BARON, AD ;
BRECHTEL, G ;
WALLACE, P ;
EDELMAN, SV .
AMERICAN JOURNAL OF PHYSIOLOGY, 1988, 255 (06) :E769-E774
[5]  
Black HR, 1998, ARCH INTERN MED, V158, P573
[6]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[7]  
DRESSMAN J, 2004, 11 C RETR OPP INF 20
[8]   Guidelines for the evaluation and management of dyslipidemia in human immunodeficiency virus (HIV)-infected adults receiving antiretroviral therapy:: Recommendations of the HIV Medicine Association of the Infectious Disease Society of America and the Adult AIDS Clinical Trials Group [J].
Dubé, MP ;
Stein, JH ;
Aberg, JA ;
Fichtenbaum, CJ ;
Gerber, JG ;
Tashima, KT ;
Henry, WK ;
Currier, JS ;
Sprecher, D ;
Glesby, MJ .
CLINICAL INFECTIOUS DISEASES, 2003, 37 (05) :613-627
[9]  
FRIEDEWALD WT, 1972, CLIN CHEM, V18, P499
[10]   Combination antiretroviral therapy and the risk of myocardial infarction [J].
Friis-Moller, N ;
Sabin, CA ;
Weber, R ;
Monforte, AD ;
El-Sadr, WM ;
Reiss, P ;
Thiébaut, R ;
Morfeldt, L ;
De Wit, S ;
Pradier, C ;
Calvo, G ;
Law, MG ;
Kirk, O ;
Phillips, AN ;
Lundgren, JD ;
Lundgren, JD ;
Weber, R ;
Monteforte, AD ;
Bartsch, G ;
Reiss, P ;
Dabis, F ;
Morfeldt, L ;
De Wit, S ;
Pradier, C ;
Calvo, G ;
Law, MG ;
Kirk, O ;
Phillips, AN ;
Houyez, F ;
Loeliger, E ;
Tressler, R ;
Weller, I ;
Friis-Moller, N ;
Sabin, CA ;
Sjol, A ;
Lundgren, JD ;
Sawitz, A ;
Rickenbach, M ;
Pezzotti, P ;
Krum, E ;
Meester, R ;
Lavignolle, V ;
Sundström, A ;
Poll, B ;
Fontas, E ;
Torres, F ;
Petoumenos, K ;
Kjær, J ;
Hammer, S ;
Neaton, J .
NEW ENGLAND JOURNAL OF MEDICINE, 2003, 349 (21) :1993-2003